Olema Oncology (OLMA) updated investors on its palazestrant pipeline at Citigroup’s Biopharma Back to School Summit on September 10, 2026, disclosing that top-line data from its Phase III OPERA-01 trial will now arrive in Q1 2027, a shift from the previously expected second half of 2026. The company also provided timelines for its OP-3136 KAT6 inhibitor program and a prostate cancer collaboration with Bayer.
OP-3136 combination data is expected in the first half of 2027, with a potential interim update by year-end. Enrollment in the prostate cancer cohort under the Bayer partnership is slated to begin in the fourth quarter of 2026.
Shares of Olema were trading around $10.22 on September 11, down roughly 58.6% year-to-date from a 52-week high of $36.26. The company has a market capitalization of approximately $937 million and reported levered free cash flow of negative $165 million over the trailing twelve months, though it maintains a current ratio of 8.86.
Palazestrant’s Phase II data showed a median progression-free survival of seven months in ESR1-mutant patients—against a historical standard of two to four months—and 5.5 months in ESR1 wild-type patients versus a typical two to three months. The compound carries a 14-day half-life with high steady-state exposure.
OPERA-01, the Phase III monotherapy study, is fully enrolled and randomized with the targeted 40% to 50% ESR1-mutant patient mix. The trial excludes patients with primary endocrine resistance, requiring at least six months on a prior endocrine regimen without progression, as well as those who previously received metastatic chemotherapy.
OPERA-02, a 1,000-patient Phase III first-line combination study comparing KISQALI plus palazestrant against KISQALI plus letrozole, showed median progression-free survival above one year in Phase II among patients who had progressed on prior CDK4/6 therapy plus an aromatase inhibitor. Roughly 30% of those patients had received two prior AIs or two prior CDK4/6 inhibitors.
President and CEO Sean Bohen said the company is the only one running a next-generation endocrine agent, a CERAN, in endocrine-sensitive patients combined with KISQALI, which he called the standard of care.
Olema outlined a global market opportunity of approximately $5 billion annually for OPERA-01 as a second- and third-line monotherapy—split between about $2 billion in the ESR1-mutant population and $3 billion in the wild-type segment. OPERA-02 in the first-line setting represents a $10 billion-plus annual opportunity, while the OP-3136 breast cancer indication carries a $5 billion-plus market potential. The U.S. is expected to contribute roughly two-thirds of global oncology revenue, and Bohen noted an adjuvant trial would cost well over $1 billion for a 4,000- to 5,000-patient study.
For commercialization, Olema plans a lean U.S. launch with fewer than 100 field sales representatives and will seek partners for international markets. The company also disclosed it licensed ChatGPT for routine work and partnered with Bay Area firm Collate for regulated document analysis, compressing tasks that previously took a month and cost hundreds of thousands of dollars into hours.
